国际医药卫生导报2017，Vol.23Issue(9)：1298-1300,3.DOI:10.3760/cma.j.issn.1007-1245.2017.09.003
贝伐单抗联合化疗治疗复发性卵巢癌的临床研究
Clinical efficacy of bevacizumab combined with chemotherapy in treatment of recurrent ovarian cancer
摘要
Abstract
Objective To investigate the clinical efficacy of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer.Methods 36 patients pathologically confirmed with recurrent ovarian cancer were selected;and all received chemotherapy with pemetrexed+ lobaplatin;3 weeks were 1 cycle;they were treated 4-6 cycles.Bevacizumab was intravenous infused 1 h before chemotherapy,7.5 mg/kg for 2 cycles.The clinical efficacy,toxicity,and survival time were observed.Results 5 cases got CR,13 PR,10 SD,and 8 PD.The RR was 50.0％(18/36).The DCR was 77.8％(28/36).The main adverse reactions were gastrointestinal reaction,bone marrow suppression,and hypertension.The OS was (15.4±2.4) months.The PFS was (10.2±2.6)months.Conclusions Bevacizumab combining chemotherapy for recurrent ovarian cancer has relatively good clinical efficacy and can be a backup treatment scheme.关键词
复发性卵巢癌/化疗/贝伐单抗/生存期/不良反应Key words
Recurrent ovarian cancer/Chemotherapy/Bevacizumab/Survival time/Adverse reactions引用本文复制引用
任莉,王焱..贝伐单抗联合化疗治疗复发性卵巢癌的临床研究[J].国际医药卫生导报,2017,23(9):1298-1300,3.基金项目
河南省科技项目(201503026)Project of Science and Technology in Hunan (201503026) （201503026）
